Resistance to Anti-CD20 Antibodies and Approaches for Their Reversal

William C.S. Cho, PhD, RCMP, FHKIMLS, FHKSMDS, Chartered Scientist (UK), FIBMS (UK). Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong SAR, China. Dr. Cho’s primary research interests focus on cancer research to discover biomarkers for cancer diagnosis, treatment prediction, and prognosis. As a seasoned researcher, Dr. Cho has conducted cancer research using molecular biology, proteomics, genomics, immunology, bioinformatics, and next-generation sequencing technologies. Dr. Cho has published more than 600 peer-reviewed papers (Lancet, Lancet Oncology, Annals of Oncology, Lancet Gastroenterology & Hepatology, Advanced Science, Nature Communications, PNAS, Molecular Cancer, Journal of Thoracic Oncology, Journal of the National Cancer Institute, Journal of Extracellular Vesicles, Clinical Cancer Research, Clinical Chemistry, Theranostics, etc.) covering cancer biomarkers, proteomics, noncoding RNA, traditional Chinese medicine, and dozens of books (including An Omics Perspective on Cancer Research, MicroRNAs in Cancer Translational Research, Drug Repurposing in Cancer Therapy: Approaches and Applications, Supportive Cancer Care with Chinese Medicine, etc.). The cumulative impact factor of journals exceeds 4500, and the papers have been cited >25,000 times. Dr. Cho is listed among the top 2% of the most influential scientists in the world. In addition, Dr. Cho has served as a research grant reviewer for many international research funds, including the Hope Funds for Cancer Research (United States), Cancer Research (United Kingdom), National Medical Research Council (Singapore), etc.

• 1. Therapeutic antibodies against cancer – A step toward the treatment2. Anti-CD20 antibody treatment for B-cell malignancies3. Anti-CD20 antibody treatment for diffuse large B cell lymphoma: Genetic alterations and signaling pathways4. Non-Hodgkin’s lymphoma treated with anti-CD20 antibody-based immunochemotherapy5. Targeted therapies for follicular lymphoma6. Treatment of relapsed follicular lymphoma7. New monoclonal antibodies for the treatment of acute lymphoblastic leukemia8. Clinical relevance and therapeutic implications of CD20 expression in Hodgkin's lymphoma9. Therapeutic options for rituximab-resistant patients10. Mechanisms of resistance to anti-CD20 antibodies in lymphoid malignancies11. Kinetic exclusion assay using cellular membranes for affinity determination of anti-CD20 antibody12. Clinical efficacy of anti-CD20 antibodies in autoimmune diseases13. B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis14. Anti-CD20 antibodies in glomerular disease, their resistance and reversal approaches15. Adverse events following rituximab therapy in pemphigus patients16. Immune monitoring of patients treated with anti-CD20 therapeutic monoclonals for autoimmune disorders17. Clinical efficacy of anti-CD20 antibodies in neurological and neuromuscular diseases18. Highlights and perspectives by the contributors of the volume (resistance to anti-CD20 antibodies and approaches for their reversals)